Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

This publication has 24 references indexed in Scilit:

• 126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study
  Lung Cancer, 1997
• Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
  Journal of Clinical Oncology, 1997
• Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
  Journal of Clinical Oncology, 1996
• Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial
  The Lancet, 1996
• In this issue
  Annals of Oncology, 1996
• Predictors of survival following relapse or progression of small cell lung cancer. Southwest oncology group study 8605 report and analysis of recurrent disease data base
  Cancer, 1993
• Management of small-cell cancer of the lung
  The Lancet, 1992
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
  Journal of Clinical Oncology, 1992
• Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1991
• A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small cell lung cancer
  Lung Cancer, 1990